Solriamfetol

Solriamfetol

SCHEMBL30929348

NC(=O)OCC(N)Cc1ccccc1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2D6 P10635 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
EPHX1 P07099 2/20 0.55
MMP2 P08253 4/20 0.53
ALPI P09923 1/20 0.52
PTGS1 P23219 1/20 0.52
XIAP P98170 1/20 0.52
SLC7A5 Q01650 1/20 0.52
LMNA P02545 1/20 0.50
SCN4A P35499 2/20 0.49
ANPEP P15144 1/20 0.48
SRR Q9GZT4 2/20 0.47
SLC1A3 P43003 1/20 0.47
SLC1A2 P43004 1/20 0.47
SLC1A1 P43005 1/20 0.47
TACR1 P25103 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Solriamfetol SCHEMBL42526 1.00 PKM (0.56) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL2739637 1.00 PKM (0.56) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL30929349 1.00 PKM (0.56) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL42525 1.00 PKM (0.56) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL8430382 0.98 PKM (0.54) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL28413501 0.98 PKM (0.54) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL4987496 0.98 PKM (0.54) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL8426383 0.98 PKM (0.54) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL30518836 0.97 PKM (0.53) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL30518840 0.95 PKM (0.51) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4626417-A1 METHODS AND COMPOSITIONS FOR IMPROVING DRIVING PERFORMANCE AXSOME THERAPEUTICS (US) 2025-10-08 EP disclosed
US-20250223281-A1 ANTIDIABETIC COMPOUNDS AND COMPOSITIONS REZUBIO PHARMACEUTICALS CO., LTD (CN) 2025-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250223281-A1 ANTIDIABETIC COMPOUNDS AND COMPOSITIONS GPR119, GLP1R, GPR65 PKM 2610/4885CYP1A2 1060/4885CYP2D6 2328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.